These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 15661529)

  • 21. Molecular neuro-oncology and the development of targeted therapeutic strategies for brain tumors. Part 4: p53 signaling pathway.
    Newton HB
    Expert Rev Anticancer Ther; 2005 Feb; 5(1):177-91. PubMed ID: 15757449
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Advances in oncolytic viral therapy.
    Woo Y; Adusumilli PS; Fong Y
    Curr Opin Investig Drugs; 2006 Jun; 7(6):549-59. PubMed ID: 16784026
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Oncogenes: the role of DNA tumor viruses in cancer.
    Benchimol S
    Curr Opin Oncol; 1990 Feb; 2(1):138-42. PubMed ID: 2095221
    [No Abstract]   [Full Text] [Related]  

  • 24. Nuclear factor-kappaB and liver carcinogenesis.
    Arsura M; Cavin LG
    Cancer Lett; 2005 Nov; 229(2):157-69. PubMed ID: 16125305
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Selective anticancer strategies via intervention of the death pathways relevant to cell transformation.
    Li QX; Yu DH; Liu G; Ke N; McKelvy J; Wong-Staal F
    Cell Death Differ; 2008 Aug; 15(8):1197-210. PubMed ID: 18437165
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Murine polyomavirus tumour specific transplantation antigens and viral persistence in relation to the immune response, and tumour development.
    Ramqvist T; Dalianis T
    Semin Cancer Biol; 2009 Aug; 19(4):236-43. PubMed ID: 19505651
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The emergence of combinatorial strategies in the development of RNA oncolytic virus therapies.
    Nguyen TL; Tumilasci VF; Singhroy D; Arguello M; Hiscott J
    Cell Microbiol; 2009 Jun; 11(6):889-97. PubMed ID: 19388908
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Thyroid receptor: roles in cancer.
    Aranda A; Martínez-Iglesias O; Ruiz-Llorente L; García-Carpizo V; Zambrano A
    Trends Endocrinol Metab; 2009 Sep; 20(7):318-24. PubMed ID: 19716314
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The SV40 large T antigen-p53 complexes bind and activate the insulin-like growth factor-I promoter stimulating cell growth.
    Bocchetta M; Eliasz S; De Marco MA; Rudzinski J; Zhang L; Carbone M
    Cancer Res; 2008 Feb; 68(4):1022-9. PubMed ID: 18281476
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Epigenetic changes in virus-associated human cancers.
    Li HP; Leu YW; Chang YS
    Cell Res; 2005 Apr; 15(4):262-71. PubMed ID: 15857581
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mechanisms of apoptosis regulation by viral oncogenes in infection and tumorigenesis.
    White E
    Cell Death Differ; 2006 Aug; 13(8):1371-7. PubMed ID: 16676007
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Natural and genetically engineered viral agents for oncolysis and gene therapy of human cancers.
    Sinkovics JG; Horvath JC
    Arch Immunol Ther Exp (Warsz); 2008 Dec; 56 Suppl 1():3s-59s. PubMed ID: 19104757
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Signal transduction cross-talk during colorectal tumorigenesis.
    Liu X; Lazenby AJ; Siegal GP
    Adv Anat Pathol; 2006 Sep; 13(5):270-4. PubMed ID: 16998321
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Molecular aspects of carcinogenesis in pancreatic cancer.
    Koliopanos A; Avgerinos C; Paraskeva C; Touloumis Z; Kelgiorgi D; Dervenis C
    Hepatobiliary Pancreat Dis Int; 2008 Aug; 7(4):345-56. PubMed ID: 18693168
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Oncolytic viral therapies - the clinical experience.
    Aghi M; Martuza RL
    Oncogene; 2005 Nov; 24(52):7802-16. PubMed ID: 16299539
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Targeted therapy of DNA tumor virus-associated cancers using virus-activated transcription factors.
    Lim MJ; Min SH; Lee JJ; Kim IC; Kim JT; Lee DC; Kim NS; Jeong S; Kim MN; Kim KD; Lim JS; Han SB; Kim HM; Heo DS; Yeom YI
    Mol Ther; 2006 May; 13(5):899-909. PubMed ID: 16461008
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dominant-negative fibroblast growth factor receptor expression enhances antitumoral potency of oncolytic herpes simplex virus in neural tumors.
    Liu TC; Zhang T; Fukuhara H; Kuroda T; Todo T; Canron X; Bikfalvi A; Martuza RL; Kurtz A; Rabkin SD
    Clin Cancer Res; 2006 Nov; 12(22):6791-9. PubMed ID: 17121900
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Fusion of the BCL9 HD2 domain to E1A increases the cytopathic effect of an oncolytic adenovirus that targets colon cancer cells.
    Fuerer C; Homicsko K; Lukashev AN; Pittet AL; Iggo RD
    BMC Cancer; 2006 Oct; 6():236. PubMed ID: 17020613
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Engineering oncolytic viruses to exploit tumor specific defects in innate immune signaling pathways.
    Naik S; Russell SJ
    Expert Opin Biol Ther; 2009 Sep; 9(9):1163-76. PubMed ID: 19637971
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Proteomics of TGF-beta signaling and its impact on breast cancer.
    Souchelnytskyi S
    Expert Rev Proteomics; 2005 Dec; 2(6):925-35. PubMed ID: 16307521
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.